Â鶹´«Ã½

The Â鶹´«Ã½ Trade Commission today announced the following actions:

• The FTC has approved the extension of a time period in the following matter: Baxter International, Inc. Under the order in Docket No. C-3726 which concerned Baxter's acquisition of Immuno International AG, Baxter was required to contract manufacture the Autoplex Factor VIII Inhibitor Treatments for NABI (the acquiring company) for a period not to exceed three years from the date the company's divestiture application was approved, unless extended by the FTC. The divestiture approval was granted on May 8, 1997, and completed on May 16, 1997. The Commission's approval in the current matter, which was requested by the trustee overseeing the divestiture process, extends by 12 months the time that NABI has to obtain all FDA approvals to manufacture Baxter's Factor VIII Inhibitor Treatments.
  
  The Commission vote to approve the time period extension was 5-0. (FTC Docket No. C-3726; staff contact is Joseph Eckhaus, 202-326-2665; see press release dated December 19, 1996 .)
  

• Following a public comment period, the Commission has made final a consent agreement with the following: Duke Energy Corporation. The Commission vote to finalize the consent order was 4-0, with Commissioner Thomas B. Leary not participating. (FTC File No. 001-0080; staff contact is Kristin L. Malmberg, Southwest Regional Office, 214-979-9381; see press release dated March 31, 2000.)

Copies of the documents mentioned in this release are available from the FTC's web site at and also from the FTC's Consumer Response Center, Room 130, 600 Pennsylvania Avenue, N.W., Washington, D.C. 20580; toll free: 877-FTC-HELP (877-382-4357); TDD for the hearing impaired 1-866-653-4261. To find out the latest news as it is announced, call the FTC NewsPhone recording at 202-326-2710.